Cornerstone Wealth Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Cornerstone Wealth Management’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$83.5K	Buy	+17,000	New	+$91.3K	﹤0.01%	740

Other funds holding VNDA

ACM

AIGH Capital Management Baltimore, Maryland $992M AUM 516.32% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Inscription Capital Houston, Texas $906M AUM 27.95% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Cornerstone Wealth Management's VNDA Position: Q3 2026 in Review

Cornerstone Wealth Management opened a new position in Vanda Pharmaceuticals (VNDA) in Q3 2026: 17,000 shares worth $83.5K. The stake represents ﹤0.01% of the portfolio and ranks #740 among its holdings.

53 funds tracked by Wall St. Rank hold VNDA as of Q3 2026.

Cornerstone Wealth Management held 17,000 shares of Vanda Pharmaceuticals worth $83.5K as of Q3 2026.
Vanda Pharmaceuticals was a new Cornerstone Wealth Management position in Q3 2026.
Vanda Pharmaceuticals made up ﹤0.01% of Cornerstone Wealth Management's portfolio in Q3 2026, its #740 holding.
53 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2026.

Based on Cornerstone Wealth Management's 13F filing for Q3 2026, filed 4 Nov 2026.